Resistance to sorafenib in HCC can also be driven by the activation of the Akt/β-catenin pathways [17], whereas the inhibition of the JAK/STAT pathways may overcome such resistance [18]. The gene discussed is SOAT1; the disease is hepatocellular carcinoma.